Sp1280
DISCOVER A DIFFERENT MECHANISM OF ACTION TO TREAT IBS-C: A CASE BASED DISCUSSI
Date
May 8, 2023
Society: DDW
Please join us for an engaging discussion led by Dr. Darren Brenner as he shares important clinical considerations in managing patients with IBS-C. The presentation will include interactive patient case studies, along with efficacy and safety data from two phase three clinical trials. Sponsored by Ardelyx
Please join us for an engaging discussion led by Dr. Darren Brenner as he shares important clinical considerations in managing patients with IBS-C. The presentation will include interactive patient case studies, along with efficacy and safety data from two phase three clinical trials. Sponsored by Ardelyx
Presenter
Tracks
Related Products
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
RNA SEQUENCING FROM BIOPSIES PERFORMED DURING FOOD ELIMINATION AND REINTRODUCTION IDENTIFIES SIGNATURES INVOLVED IN EARLY RECURRENCE OF EOE
RATIONALE: RNA sequencing studies have previously identified impaired barrier function and the subsequent proinflammatory response as critical to the pathogenies of EoE. However, the investigation into disease initiation is often limited by the inability to capture the disease early…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
INVESTIGATING THE EFFICACY OF ALPELISIB AND PI3Kα-S6K DUAL INHIBITION IN LIN28B-DRIVEN COLORECTAL CANCER METASTASIS
Colorectal cancer (CRC) shows a dramatic drop in the five-year survival rate from 90% for localized tumors to 14% for metastatic CRC (mCRC). Our lab has identified LIN28B, an RNA-binding protein overexpressed in 30% of CRCs, as an oncogene that promotes CRC metastasis…
